sign in sign up
<<
Home , Axitinib, Filgotinib

NICE Technology Appraisals About Medicines: Formulary Adherence Checklist This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS. Last updated 28-Apr-21 Technology appraisal Date of TA Availability of medicine for NHS patients with this Adherence of local formulary to NICE (TA) Release medical condition, as indicated by NICE Titles are hyperlinks to N/A Notes (e.g. rationale, method of making Comments Yes Date of local Date of local Time to full guidance available) (mark 'x' decision decision implement (mark 'x' if if applicable) Due (90 days) Made (days) applicable) 2020-21 TA626 - Evidence-based recommendations on avatrombopag Alcohol-use disorders Same indication as TA617 therefore Avatrombopag for (Doptelet) for treating severe in Cirrhosis will use Lusutrombopag instead so treating adults with chronic disease needing a planned Non-alcoholic will not be used thrombocytopenia in invasive procedure. Fatty liver disease people with chronic Liver cancers liver disease needing a The scope for this multiple technology appraisal 1 planned invasive 24/06/2020 included both avatrombopag and lusutrombopag. X 22/09/2020 11/08/2020 48 procedure However, because of a delay in getting an agreed list price for avatrombopag, this topic was split into 2 separate appraisals. Please see NICE technology appraisal guidance 617 for recommendations on lusutrombopag.

TA627 - Evidence-based recommendations on lenalidomide with for (Revlimid) with rituximab for previously treated 1 previously treated 07/04/2020 follicular (grade 1 to 3A) in adults. X 06/07/2020 07/04/2020 0 Non-Hodgkin’s lymphoma follicular lymphoma

TA628 - Orlatinib for Evidence-based recommendations on N/A @ SRFT previously treated ALK- (Lorviqua) for previously treated ALK-positive positive advanced non- advanced non-small-cell lung cancer in adults. 1 small-cell lung cancer 13/05/2020 X 11/08/2020 31/05/2020 18 Lung cancer

TA629 - Evidence-based recommendations on obinutuzumab with bendamustine for (Gazyvaro) with bendamustine for follicular lymphoma treating follicular that has not responded or has progressed up to 6 1 13/05/2020 X 11/08/2020 16/06/2020 34 Non-Hodgkin’s lymphoma lymphoma after months after treatment with rituximab or a rituximab- rituximab containing regimen in adults.

TA630 - Evidence-based recommendations on larotrectinib N/A @ SRFT for treating NTRK (Vitrakvi) for treating neurotrophic tyrosine receptor fusion-positive solid kinase (NTRK) fusion-positive solid tumours in adults tumours and children.

Genomic biomarker-based treatment 1 27/05/2020 X 25/08/2020 24/06/2020 28 for solid tumours

TA631 - Evidence-based recommendations on fremanezumab Fremanezumab for (Ajovy) for preventing chronic migraine in adults. preventing migraine 1 03/06/2020 X 01/09/2020 02/07/2020 29 Headaches

TA632 - Evidence-based recommendations on trastuzumab N/A @ SRFT emtansine for adjuvant emtansine (Kadcyla) for human epidermal growth treatment of HER2- factor receptor 2 (HER2)‑positive early breast cancer Early and locally advanced breast 1 positive early breast 10/06/2020 in adults who have residual invasive disease in the X 08/09/2020 24/06/2020 14 cancer cancer breast or lymph nodes after neoadjuvant taxane- based and HER2‑.

TA633 - Evidence-based recommendations on ustekinumab for treating moderately (Stelara) for treating moderately to severely active 1 to severely active 17/06/2020 ulcerative colitis in adults. X 15/09/2020 15/10/2020 120 Ulcerative colitis ulcerative colitis

TA634 - Advice - NICE is unable to make a recommendation Information - If NHS organisations with lenalidomide and about the use in the NHS of daratumumab with wish to consider daratumumab with for lenalidomide and dexamethasone for untreated lenalidomide and dexamethasone for untreated multiple multiple myeloma because Janssen did not provide untreated multiple myeloma, they myeloma (terminated an evidence submission. The company has should follow the advice on rational appraisal) confirmed that it does not intend to make a local decision making in the NHS 1 30/06/2020 X 28/09/2020 11/08/2020 42 Myeloma submission for the appraisal because the technology Constitution for England and the is unlikely to be a cost-effective use of NHS NHS Commissioning Board and resources. Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012.

TA635 - Advice - NICE is unable to make a recommendation Information - If NHS organisations with for about the use in the NHS of ramucirumab with wish to consider ramucirumab with untreated EGFR- erlotinib for untreated epidermal erlotinib for untreated EGFR-positive positive metastatic non- receptor (EGFR)-positive metastatic non-small-cell metastatic non-small-cell lung small-cell lung cancer lung cancer because Eli Lilly and Company Limited cancer, they should follow the advice (terminated appraisal) did not provide an evidence submission. The on rational local decision making in 1 30/06/2020 company has confirmed that it does not intend to X 28/09/2020 11/08/2020 42 Lung cancer the NHS Constitution for England make a submission for the appraisal because the and the NHS Commissioning Board technology is unlikely to be a cost‑effective use of and Clinical Commissioning Groups NHS resources. (Responsibilities and Standing Rules) Regulations 2012.

TA636 - Advice - NICE is unable to make a recommendation Information - If NHS organisations for treating refractory about the use in the NHS of eculizumab for treating wish to consider eculizumab for myasthenia gravis refractory myasthenia gravis because Alexion treating refractory myasthenia (terminated appraisal) Pharma UK did not provide an evidence submission. gravis, they should follow the advice The company has confirmed that it does not intend to on rational local decision making in 1 30/06/2020 make a submission for the appraisal because the X 28/09/2020 11/08/2020 42 Neurological conditions the NHS Constitution for England technology will not be launched in the UK for this and the NHS Commissioning Board indication. and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012.

TA637 - Advice - NICE is unable to make a recommendation Information - If NHS organisations for treating diabetic about the use in the NHS of ranibizumab for treating wish to consider ranibizumab for retinopathy diabetic retinopathy because Novartis did not provide treating diabetic retinopathy they (terminated appraisal) an evidence submission. The company has should follow the advice on rational confirmed that it does not intend to make a local decision making in the NHS submission for the appraisal because it will not add Constitution for England and the value. Most people with proliferative diabetic NHS Commissioning Board and retinopathy will also have diabetic macular oedema, Clinical Commissioning Groups and these people can already have ranibizumab in Type 1 Diabetes in adults (Responsibilities and Standing 1 30/06/2020 X 28/09/2020 11/08/2020 42 England and Wales (NICE technology appraisal Type 2 Diabetes in adults Rules) Regulations 2012. This guidance 274). For people with proliferative diabetic outlines the approach that should be retinopathy with no macular involvement, panretinal taken when there is no NICE photocoagulation is the preferred treatment. There is guidance. unlikely to be sufficient evidence that ranibizumab is a cost-effective use of NHS resources compared with panretinal photocoagulation. Technology appraisal Date of TA Availability of medicine for NHS patients with this Adherence of local formulary to NICE (TA) Release medical condition, as indicated by NICE Titles are hyperlinks to N/A Notes (e.g. rationale, method of making Comments Yes Date of local Date of local Time to full guidance available) (mark 'x' decision decision implement (mark 'x' if if applicable) Due (90 days) Made (days) applicable) 2020-21 TA638 - 01/07/2020 Evidence-based recommendations on atezolizumab N/A @ SRFT with carboplatin and (Tecentriq) for untreated extensive-stage small-cell etoposide for untreated lung cancer in adults. 1 extensive-stage small- X 29/09/2020 11/08/2020 41 Lung cancer cell lung cancer

TA639 - Atezolizumab 01/07/2020 Evidence-based recommendations on atezolizumab N/A @ SRFT with nab-paclitaxel for (Tecentriq) with nab‑paclitaxel for triple-negative, untreated PD-L1- unresectable, PD‑L1‑positive, locally advanced or positive, locally metastatic breast cancer in adults who have not had 1 advanced or for metastatic disease. X 29/09/2020 11/08/2020 41 Advanced breast cancer metastatic, triple- negative breast cancer

TA640 - Treosulfan 05/08/2020 Evidence-based recommendations on treosulfan N/A @ SRFT with fludarabine for (Trecondi) with fludarabine for conditioning treatment malignant disease before allogeneic haematopoietic stem cell transplant 1 X 03/11/2020 11/08/2020 6 Myeloma before allogeneic stem for malignant diseases in people for whom a reduced cell transplant intensity regimen would be suitable.

TA641 - Brentuximab 12/08/2020 Evidence-based recommendations on in combination vedotin (Adcetris) with cyclophosphamide, for untreated systemic doxorubicin and prednisone for untreated systemic 1 anaplastic large cell anaplastic large cell lymphoma in adults. X 10/11/2020 06/09/2020 25 Non-Hodgkin’s lymphoma lymphoma

TA642 - for 12/08/2020 Evidence-based recommendations on gilteritinib treating relapsed or (Xospata) for relapsed or refractory FLT3-mutation- 1 X 10/11/2020 15/10/2020 64 Blood and bone marrow cancers refractory acute positive acute myeloid leukaemia in adults. myeloid leukaemia TA643 - for 12/08/2020 Evidence-based recommendations on entrectinib N/A @ SRFT treating ROS1-positive (Rozlytrek) for ROS1-positive advanced non-small- 1 advanced non-small- cell lung cancer (NSCLC) in adults who have not had X 10/11/2020 06/09/2020 25 Lung cancer cell lung cancer ROS1 inhibitors.

TA644 - Entrectinib for 12/08/2020 Evidence-based recommendations on entrectinib N/A @ SRFT treating NTRK fusion- (Rozlytrek) for treating neurotrophic tyrosine receptor Genomic biomarker-based treatment 1 X 10/11/2020 06/09/2020 25 positive solid tumours kinase (NTRK) fusion-positive solid tumours in adults for solid tumours and children over 12 years. TA645 - 02/09/2020 Evidence-based recommendations on avelumab N/A @ SRFT with for (Bavencio) with axitinib (Inlyta) for untreated untreated advanced advanced in adults. renal cell carcinoma

1 X 01/12/2020 06/09/2020 4 Renal cancer

TA646 - 02/09/2020 NICE is unable to make a recommendation about N/A @ SRFT with chemotherapy for the use in the NHS of glasdegib with chemotherapy untreated acute for untreated acute myeloid leukaemia because myeloid leukaemia did not provide an evidence submission. The (terminated appraisal) company has confirmed that it does not intend to make a submission for the appraisal because the technology is unlikely to be a cost-effective use of 1 NHS resources. X 01/12/2020 06/09/2020 4 Blood and bone marrow cancers

TA647 - Eculizumab 02/09/2020 NICE is unable to make a recommendation about N/A @ SRFT for treating relapsing the use in the NHS of eculizumab (Soliris) for treating neuromyelitis optica relapsing neuromyelitis optica because Alexion (terminated appraisal) Pharma UK did not provide an evidence submission. The company has confirmed that it does not intend to 1 make a submission for the appraisal because the X 01/12/2020 06/09/2020 4 Blood and immune system conditions technology will not be launched in the UK for this indication.

TA648 - Dupilumab for 09/09/2020 NICE is unable to make a recommendation on N/A @ SRFT treating chronic dupilumab (Dupixent) for treating chronic rhinosinusitis with rhinosinusitis with nasal polyps because Sanofi did 1 nasal polyps not provide an evidence submission. We will review X 08/12/2020 13/10/2020 34 Ear, nose and throat conditions (terminated appraisal) this decision if the company decides to make a submission.

TA649 - Polatuzumab 23/09/2020 Evidence-based recommendations on with rituximab vedotin (Polivy) with rituximab and bendamustine for and bendamustine for treating relapsed or refractory diffuse large B-cell treating relapsed or lymphoma in adults who cannot have a 1 X 22/12/2020 16/10/2020 23 refractory diffuse large haematopoietic stem cell transplant. Non-Hodgkin’s lymphoma B-cell lymphoma

TA650 - 30/09/2020 Evidence-based recommendations on N/A @ SRFT with pembrolizumab (Keytruda) with axitinib (Inlyta) for axitinib for untreated untreated advanced renal cell carcinoma in adults. advanced renal cell carcinoma 1.1 Pembrolizumab with axitinib is not recommended, within its marketing authorisation, for untreated advanced renal cell carcinoma in adults.

1.2 This recommendation is not intended to affect 1 X 29/12/2020 13/10/2020 13 Renal cancer treatment with pembrolizumab plus axitinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

30/09/2020 TA651 - Naldemedine Evidence-based recommendations on naldemedine for treating opioid- 1 (Rizmoic) for treating opioid-induced constipation in X 29/12/2020 18/02/2021 141 Constipation induced constipation adults who have had laxative treatment. Technology appraisal Date of TA Availability of medicine for NHS patients with this Adherence of local formulary to NICE (TA) Release medical condition, as indicated by NICE Titles are hyperlinks to N/A Notes (e.g. rationale, method of making Comments Yes Date of local Date of local Time to full guidance available) (mark 'x' decision decision implement (mark 'x' if if applicable) Due (90 days) Made (days) applicable) 2020-21 TA652 - Alpelisib with 07/10/2020 NICE is unable to make a recommendation on N/A @ SRFT fulvestrant for treating alpelisib (Piqray) with fulvestrant for treating hormone- hormone-receptor receptor positive, HER2-negative, PIK3CA-positive positive, HER2- advanced breast cancer because Novartis did not 1 negative, PIK3CA- provide an evidence submission. We will review this X 05/01/2021 13/10/2020 6 Advanced breast cancer positive advanced decision if the company decides to make a breast cancer submission. (terminated appraisal) TA653 - 14/10/2020 Evidence-based recommendations on osimertinib N/A @ SRFT for treating EGFR (Tagrisso) for treating T790M mutation- receptor (EGFR) T790M mutation-positive locally positive advanced non- advanced or metastatic non-small-cell lung cancer small-cell lung cancer (NSCLC) in adults. . 1 This guidance updates and replaces NICE X 12/01/2021 30/11/2020 47 Lung cancer technology appraisal guidance 416 on osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non- small-cell lung, which was available through the Cancer Drugs Fund. TA654 - Osimertinib 14/10/2020 Evidence-based recommendations on osimertinib N/A @ SRFT for untreated EGFR (Tagrisso) for untreated locally advanced or mutation-positive non- metastatic epidermal (EGFR) small-cell lung cancer mutation-positive non-small-cell lung cancer in adults.

1 X This guidance updates and replaces NICE 12/01/2021 30/11/2020 47 Lung cancer technology appraisal guidance 621 on osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer.

TA655 - for 21/10/2020 Evidence-based recommendations on nivolumab N/A @ SRFT advanced squamous (Opdivo) for advanced squamous non-small-cell lung non-small-cell lung cancer in adults after chemotherapy. cancer after 1 chemotherapy This guidance updates and replaces NICE X 19/01/2021 30/11/2020 40 Lung cancer technology appraisal guidance 483 on nivolumab for previously treated squamous non-small-cell lung cancer, which was available through the Cancer Drugs Fund. TA656 - for 18/11/2020 Evidence-based recommendations on siponimod treating secondary (Mayzent) for treating secondary progressive multiple progressive multiple sclerosis in adults. 1 sclerosis X 16/02/2021 08/12/2020 20 Multiple sclerosis

TA657 - Carfilzomib for 18/11/2020 Evidence-based recommendations on carfilzomib previously treated (Kyprolis) for previously treated multiple myeloma in multiple myeloma adults.

The treatments for multiple myeloma in the NHS have changed since this guidance was first published. So we have updated the recommendations in section 1 of the guidance and explained this change in sections 4.25 and 4.26. No other sections of the guidance have been updated, so these are the same as in the original guidance. 1 X 16/02/2021 18/12/2020 30 Myeloma A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions on using carfilzomib. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.

This guidance updates and replaces NICE technology appraisal guidance on carfilzomib for previously treated multiple myeloma (TA457) TA658 - 18/11/2020 Evidence-based recommendations on isatuximab with and (Sarclisa) with pomalidomide and dexamethasone for dexamethasone for treating relapsed and refractory multiple myeloma in treating relapsed and adults. refractory multiple myeloma 1 X 16/02/2021 18/12/2020 30 Myeloma

TA659 - 18/11/2020 Evidence-based recommendations on galcanezumab Update 28th April '21: Still pending Galcanezumab for (Emgality) for preventing migraine in adults. commissioning position preventing migraine

1 X 16/02/2021 Headaches

TA660 - Darolutamide 25/11/2020 Evidence-based recommendations on darolutamide with androgen (Nubeqa) for treating hormone-relapsed prostate deprivation therapy for cancer in adults at high risk of developing metastatic 1 treating hormone- disease. X 23/02/2021 Prostate cancer relapsed non- metastatic prostate TA661cancer - 25/11/2020 Evidence-based recommendations on N/A @ SRFT Pembrolizumab for pembrolizumab (Keytruda) for untreated metastatic or untreated metastatic or unresectable recurrent head and neck squamous cell 1 unresectable recurrent carcinoma (HNSCC) in adults whose tumours X 23/02/2021 30/11/2020 5 Upper aerodigestive tract cancer head and neck express PD L1 with a combined positive score (CPS) squamous cell of 1 or more. carcinoma Technology appraisal Date of TA Availability of medicine for NHS patients with this Adherence of local formulary to NICE (TA) Release medical condition, as indicated by NICE Titles are hyperlinks to N/A Notes (e.g. rationale, method of making Comments Yes Date of local Date of local Time to full guidance available) (mark 'x' decision decision implement (mark 'x' if if applicable) Due (90 days) Made (days) applicable) 2020-21 TA662 - in 25/11/2020 NICE is unable to make a recommendation about Lung cancer N/A @ SRFT combination for the use in the NHS of durvalumab in combination for untreated extensive- untreated extensive-stage small-cell lung cancer stage small-cell lung because AstraZeneca withdrew its evidence cancer (terminated submission. The company has confirmed that it does appraisal) not intend to make a submission for the appraisal because the technology is unlikely to be a cost- effective use of NHS resources.

1 If NHS organisations wish to consider durvalumab in X 23/02/2021 30/11/2020 5 combination for untreated extensive-stage small-cell lung cancer, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

TA663 - 09/12/2020 Evidence-based recommendations on venetoclax Blood and bone marrow cancers with obinutuzumab for (Venclyxto) with obinutuzumab for untreated chronic Next 1 untreated chronic lymphocytic leukaemia in adults. X 09/03/2021 18/01/2021 40 lymphocytic leukaemia

TA664 - Liraglutide for 09/12/2020 Evidence-based recommendations on liraglutide Obesity Update 28th April '21: Pending - managing overweight (Saxenda) for managing overweight and obesity Preventing type 2 diabetes awaiting commissioning decision and obesity alongside a reduced-calorie diet and increased physical activity in adults.

This guidance covers the management of obesity and non-diabetic hyperglycaemia (pre-diabetes) in a specialist weight management (tier 3) service.

It should be used alongside NICE's guideline on type 2 diabetes: prevention in people at high risk.

1 It is expected that most people will have been offered X 09/03/2021 weight management interventions in a local, evidence- based, quality-assured intensive lifestyle-change programme (such as the NHS diabetes prevention programme). This guidance covers people who have been referred to a tier 3 service because these weight management interventions have been unsuccessful. . This guidance replaces the NICE evidence summary on obese, overweight with risk factors: liraglutide (Saxenda) (ES14).

TA665 - 09/12/2020 Evidence-based recommendations on upadacitinib for treating severe (Rinvoq) for severe active rheumatoid arthritis in rheumatoid arthritis adults.

This guidance only includes recommendations for 1 treating severe rheumatoid arthritis. The scope for X 09/03/2021 this technology appraisal also included moderate rheumatoid arthritis, which will continue to be considered by NICE in a separate technology appraisal on upadacitinib for treating moderate rheumatoid arthritis. TA666 - Atezolizumab 16/12/2020 Evidence-based recommendations on atezolizumab Liver cancers N/A @ SRFT with for (Tecentriq) with bevacizumab (Avastin) for treating treating advanced or advanced or unresectable hepatocellular carcinoma unresectable in adults who have not had previous systemic hepatocellular treatment. 1 X 16/03/2021 17/01/2021 32 carcinoma The recommendations also apply to bevacizumab biosimilar products that have a marketing authorisation allowing them to be used for the same indication. TA667 - Caplacizumab 16/12/2020 Evidence-based recommendations on caplacizumab Blood and immune system conditions N/A @ SRFT with plasma exchange (Cablivi) with plasma exchange and and for treating acute acquired immunosuppression thrombotic thrombocytopenic purpura in adults, and 1 for treating acute in young people aged 12 years and over who weigh X 16/03/2021 28/04/2021 133 acquired thrombotic at least 40 kg. thrombocytopenic purpura

TA668 - 06/01/2021 Evidence-based recommendations on encorafenib Colorectal cancer N/A @ SRFT plus for (Braftovi) plus cetuximab (Erbitux) for treating BRAF previously treated V600E mutation-positive metastatic colorectal cancer BRAF V600E mutation- in adults who have had previous systemic treatment. 1 X 06/04/2021 17/01/2021 11 positive metastatic colorectal cancer TA668 06 January 2021 TA669 - 27/01/2021 Evidence-based recommendations on Oesophageal and gastric cancer N/A @ SRFT Trifluridine–tipiracil for trifluridine–tipiracil (Lonsurf) for treating metastatic treating metastatic gastric cancer or gastro-oesophageal junction gastric cancer or adenocarcinoma in adults after 2 or more therapies. gastro-oesophageal junction Trifluridine–tipiracil is not recommended, within adenocarcinoma after its marketing authorisation, for treating metastatic 2 or more therapies gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more systemic treatment regimens. 1 X 27/04/2021 15/02/2021 19 1.2This recommendation is not intended to affect treatment with trifluridine–tipiracil that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

TA670 - for 27/01/2021 Evidence-based recommendations on brigatinib Lung cancer N/A @ SRFT ALK-positive advanced (Alunbrig) for anaplastic lymphoma kinase (ALK)- non-small-cell lung positive advanced non-small-cell lung cancer that has 1 cancer that has not not been previously treated with an ALK inhibitor. X 27/04/2021 15/02/2021 19 been previously treated with an ALK inhibitor Technology appraisal Date of TA Availability of medicine for NHS patients with this Adherence of local formulary to NICE (TA) Release medical condition, as indicated by NICE Titles are hyperlinks to N/A Notes (e.g. rationale, method of making Comments Yes Date of local Date of local Time to full guidance available) (mark 'x' decision decision implement (mark 'x' if if applicable) Due (90 days) Made (days) applicable) 2020-21 TA671 - 03/02/2021 Evidence-based recommendations on mepolizumab Asthma for treating severe (Nucala) for treating severe eosinophilic asthma in eosinophilic asthma adults.

1 This guidance updates and replaces NICE X 04/05/2021 04/05/2021 90 technology appraisal guidance 431.

TA672 - 03/02/2021 Evidence-based recommendations on brolucizumab Age-related macular degeneration N/A @ SRFT for treating wet age- (Beovu) for treating wet age-related macular 1 related macular degeneration in adults. X 04/05/2021 17/02/2021 14 degeneration

TA673 - Niraparib for 17/02/2021 Evidence-based recommendations on niraparib Ovarian cancer N/A @ SRFT maintenance treatment (Zejula) for maintenance treatment of advanced of advanced ovarian, (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube and fallopian tube or primary peritoneal cancer after 1 peritoneal cancer after response to first-line platinum-based chemotherapy in X 18/05/2021 18/03/2021 29 response to first-line adults. platinum-based chemotherapy

TA674 - 17/02/2021 NICE is unable to make a recommendation on Bladder cancer Pembrolizumab for pembrolizumab (Keytruda) for untreated PD-L1- untreated PD-L1- positive, locally advanced or metastatic urothelial positive, locally cancer when cisplatin is unsuitable in adults. This is advanced or because Merck Sharp & Dohme did not provide a metastatic urothelial complete evidence submission. cancer when cisplatin This advice updates and replaces NICE 1 X 18/05/2021 09/03/2021 20 N/A is unsuitable technology appraisal guidance 522 on (terminated appraisal) pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable, which was available through the Cancer Drugs Fund. People already taking it will be able to continue until they and their doctor decide when best to stop. TA675 - Vernakalant 17/02/2021 NICE is unable to make a recommendation on Atrial fibrillation for the rapid vernakalant (Brinavess) for the rapid conversion of conversion of recent recent onset atrial fibrillation to sinus rhythm in adults. 1 onset atrial fibrillation This is because Correvio Ltd did not provide an X 18/05/2021 09/03/2021 20 N/A to sinus rhythm evidence submission. We will review this decision if (terminated appraisal) the company decides to make a submission.

TA676 - for 24/02/2021 Evidence-based recommendations on filgotinib Rheumatoid arthritis treating moderate to (Jyseleca) for moderate to severe rheumatoid arthritis severe rheumatoid in adults. arthritis 1 X 25/05/2021

TA677 - Autologous 24/02/2021 Evidence-based recommendations on autologous Non-Hodgkin’s lymphoma N/A @ SRFT anti-CD19-transduced anti-CD19-transduced CD3+ cells for treating CD3+ cells for treating relapsed or refractory mantle cell lymphoma in adults 1 X 25/05/2021 28/04/2021 63 relapsed or refractory who have previously had a Bruton’s mantle cell lymphoma (BTK) inhibitor.

TA678 - 24/02/2021 NICE is unable to make a recommendation on Ear, nose and throat conditions for treating chronic omalizumab (Xolair) for treating chronic rhinosinusitis rhinosinusitis with with nasal polyps in adults because Novartis 1 nasal polyps Pharmaceuticals did not provide an evidence X 25/05/2021 09/03/2021 13 N/A (terminated appraisal) submission. We will review this decision if the company decides to make a submission.

TA679 - Dapagliflozin 24/02/2021 Evidence-based recommendations on dapagliflozin Chronic heart failure for treating chronic (Forxiga) for symptomatic chronic heart failure with 1 heart failure with reduced ejection fraction in adults. X 25/05/2021 reduced ejection fraction TA680 - Lenalidomide 03/03/2021 Evidence-based recommendations on lenalidomide Myeloma maintenance treatment (Revlimid) for maintenance treatment after an after an autologous autologous stem cell transplant for newly diagnosed stem cell transplant for multiple myeloma in adults. 1 newly diagnosed X 01/06/2021 10/03/2021 7 multiple myeloma The use of lenalidomide as a maintenance treatment after an autologous stem cell transplant at a dosage of 10 mg per day on days 1 to 21 of a 28-day cycle is outside the terms of the marketing authorisation for TA681 - for 03/03/2021 Evidence-based recommendations on baricitinib for Eczema treating moderate to treating moderate to severe atopic dermatitis in 1 X 01/06/2021 severe atopic dermatitis adults.

20 36 Average 56 % "Yes" % "N/A" implement time (days)

Adherence statistics for 2020-21 36% 64% 34

N.B. The actual publication date for each NICE TA is printed on the PDF document for each NICE TA. Although most are published on the 4th Wednesday of each month.